Wipro GE HealthCare has made an incredibly bold statement with its investment that would elevate the quality and performance of health technology in India to unprecedented heights. The company has committed to allocating more than Rs 8000 crores (approximately $1 billion) over the following five years. 

This decision not only reaffirms but also reinforces the business’s unyielding faith in enhancing the manufacturing output and inspiring research and development in the local community. While delivering an exemplary speech during the much celebrated GE healthcare India event at Bengaluru, Peter J Arduini (President and CEO of GE HealthCare Technologies) made accent that India was the keystone of the firm’s recently disclosed high-potential, high-priority markets strategy. 

He highlighted the business mission to strengthen the country’s domestic proficiency and at the same time to extend the company’s net network on product-making and R&D practices worldwide. This announcement marks Peter J Arduini’s inaugural visit to India following GE HealthCare’s transition into an independent entity, listed on the prestigious Nasdaq stock exchange in January 2023 subsequent to its spin-off from General Electric Company.

What is more is that John F. Welch Technology Centre is located in Bengaluru, and since it has been in operation for over 25 years, it stands proudly as the largest integrated R&D unit outside the US of General Electric. 

The separation of GE into three different independent segments including healthcare means each segment has its own R&D department, which was previously situated at the technology center, around a decade ago and now operates under a new name called HealthCare Technology Centre India (HTCI). Boasting a workforce comprising about 1,800 engineers, scientists and domain experts, HTCI is now in a position to assume a critical role in GE HealthCare’s ambitious AI technologies.

Arduini has a vision of GE Healthcare not just as a medical device provider but an advanced medical technology company, stabilized on a very precise and patient personalized care solutions outlook. Amidst the rising changes, Mr. Azim Premji, the chairman of Wipro Enterprises and Wipro GE HealthCare highlighted on the strategic focus of the company which will give localization a big boost for the products. 

Product expansion as a result will not just be expanded nationwide but also across the nation. Through this, the government is asserting that India is now a number one choice of the world counter to offering the production bases of the supply chains to China. Here, two notable disruptions can be observed and the subsequent two initiatives of GE Wipro HealthCare seem to be responding to these changes in the Indian medical devices industry that is poised to reach $50 billion by the next five years. 

Through such a practice, Wipro GE HealthCare reaffirms its devotion to creativity and superiority in various categories. The organization is thus set to export its Discovery IQ PET CT, the world-class product with respect to 15 countries. By implication, the company manufactures also the globally competitive products like the baby incubators for various export markets.

The Leaders Globe

Welcome to The Leaders Globe. This is the largest online and print community platform to acquaint with the global Leaders from diverse industries who make the world a better place. Our aim is to divulge the secrets of the global solution and service leader providers’ success.

Follow Us

© 2016-2023 TLG MEDIA LLP. ALL RIGHTS RESERVED.